Gelesis Holdings Inc (GLSHQ)

0.00 USD  |  OTCM  |  Apr 26, 16:00
More

Price Chart

Key Stats

View All Stats
Price and Performance
Market Cap 0.00
52 Week High (Daily) Upgrade
52 Week Low (Daily) Upgrade
All-Time High (Daily) Upgrade
Year to Date Total Returns (Daily) Upgrade
1 Month Total Returns (Daily) Upgrade
1 Year Total Returns (Daily) --
Valuation
PE Ratio --
PE Ratio (Forward) Upgrade
PS Ratio --
Price to Book Value --
EV to EBITDA Upgrade
Dividend
Dividend --
Dividend Yield (Forward) Upgrade
Financials
Revenue (5 Year Growth) Upgrade
Revenue (Quarterly YoY Growth) Upgrade
EPS Diluted (5 Year Growth) Upgrade
EPS Diluted (Quarterly YoY Growth) Upgrade
Debt to Equity Ratio -1.923
Return on Equity Upgrade
Return on Assets Upgrade
Risk
Beta (5Y) Upgrade
Max Drawdown (5Y) --

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
URL https://www.gelesis.com
Investor Relations URL https://ir.gelesis.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release May. 15, 2024 (est.)
Last Earnings Release Aug. 14, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ratings

Y-Rating Upgrade
Value Score Upgrade
Fundamental Score Upgrade
Valuation (Hist. Mult.) Upgrade

Profile

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
URL https://www.gelesis.com
Investor Relations URL https://ir.gelesis.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style N/A
Next Earnings Release May. 15, 2024 (est.)
Last Earnings Release Aug. 14, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A